Human Longevity closes $220mm Series B round

Human Longevity Inc. (HLI) raised $220mm through its Series B round from investors including Illumina, Celgene, GE Ventures, and buyers from the firm's Series A round (which closed at $80mm late last year). The company, which is creating a database of whole genome, phenotype, and clinical data for therapeutic and diagnostic use, will put the Series B money towards expansion of its products, including supporting HLI's first Health Nucleus division, a genomic enhanced health center, and growing HLI's Knowledgebase of genomic and phenotypic data.